Clinical Trial Update: Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014) [Phase 1]

View source ↗

Summary

Phase 1 trial MK-8507 (Ulonivirine) is evaluating the drug in participants with hepatic impairment. The study status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Disease

Drugs mentioned

• Ulonivirine (MK-8507)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatic Insufficiency | Phase 1 | Status: NOT_YET_RECRUITING